Alisertib (MLN8237)

目录号:S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237)是一种选择性Aurora A抑制剂,无细胞试验中IC50为1.2 nM,作用于Aurora A比作用于Aurora B选择性强200倍以上。Phase 3。

规格 价格 库存 购买数量  
RMB 1375.12 现货
RMB 983.87 现货
RMB 1725.78 现货
RMB 5505.84 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献48篇:

客户使用该产品的12个实验数据:

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述 Alisertib (MLN8237)是一种选择性Aurora A抑制剂,无细胞试验中IC50为1.2 nM,作用于Aurora A比作用于Aurora B选择性强200倍以上。Phase 3。
特性 MLN8237 是第一个口服有效的小分子Aurora A激酶选择性抑制剂。
靶点
Aurora A [1]
(Cell-free assay)
1.2 nM
体外研究

MLN8237作用于Aurora A选择性比作用于结构相关的Aurora B 高200多倍,IC50为396.5 nM, 而对205种其他激酶则没有显著活性。[1] 0.5 μM MLN8237处理MM1.S和 OPM1 细胞,抑制 Aurora A磷酸化,而不影响 Aurora B调节的组蛋白H3磷酸化。MLN8237作用于多发性骨髓瘤(MM) 细胞系,显著抑制细胞增殖,IC50为0.003-1.71 μM。在BM 基质细胞,IL-6和 IGF-1 存在时,MLN8237作用于原代MM 细胞和MM细胞系,抗增殖活性比只有MLN8237单独作用时高很多。0.5 μM MLN8237 作用于原代MM细胞和细胞系,使G2/M 期细胞提高2到6倍,且显著诱导凋亡和衰老,涉及p53, p21 和p27的上调,及 PARP,caspase 3,和 caspase 9的裂解。此外, MLN8237和 Dexamethasone联用具有协同作用,具有强抗MM 功效, 而和Doxorubicin 及Bortezomib联用则具有另外的功能。[2] 0.5 μM MLN8237处理 FLO-1, OE19, 和OE33 食管腺癌细胞系,抑制集落形成,且显著提高多倍体细胞百分数,随后提高G1期细胞百分数,而与 Cisplatin (2.5 μM)联用则效果进一步提高,与单独用药相比,诱导产生更多, TAp73β, PUMA, NOXA, cleaved caspase-3, 和cleaved PARP。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 NHi0V|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHWNE42KM7:TR?= MV[3NkBp M1zqeGROW09? Mnf2TWM2OD1yLkC0JO69VQ>? NYf0Z|NQOjZzM{[2PFQ>
LS174T MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfsPZAxNjVizszN M3\ke|czKGh? NFzzNJhFVVOR MmfJTWM2OD1yLkC1JO69VQ>? NWLW[IkxOjZzM{[2PFQ>
T84 NIXyWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmwMlUh|ryP NGTVNoE4OiCq M3;ZTWROW09? M{fRVGlEPTB;MD6wPUDPxE1? MWeyOlE{PjZ6NB?=
LS180 NXTPbphLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[4W|AvPSEQvF2= M3rKeVczKGh? NILTVZNFVVOR NF\NU29KSzVyPUGg{txO NX;QXXJ5OjZzM{[2PFQ>
SW948 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDHTGc1OC53IN88US=> MVm3NkBp NXW1ZW5uTE2VTx?= NWqwOJAzUUN3ME2xJO69VQ>? M{nk[FI3OTN4Nki0
HCT15 NYPvdVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL2T2oxNjVizszN M4TaeVczKGh? NEPPUXpFVVOR NIe5UY9KSzVyPECuOEDPxE1? M3KzS|I3OTN4Nki0
DLD-1 M12yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMlUh|ryP M1HQdlczKGh? NUC0VFZnTE2VTx?= M3;RZ2lEPTB:MD64JO69VQ>? MX[yOlE{PjZ6NB?=
MIP-101 NIW1UmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17QNlAvPSEQvF2= MmC5O|IhcA>? M4W5[WROW09? NY\Fd|VyUUN3ME2xJO69VQ>? MU[yOlE{PjZ6NB?=
SNU1544 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYiwMlUh|ryP M2\FZVczKGh? MmLISG1UVw>? NV3YVXhnUUN3ME2xJO69VQ>? M4frb|I3OTN4Nki0
OCI-Ly10 NYnPdph7S3m2b4TvfIlkKEG|c3H5 NUH6bGt2PzJiaB?= MXPEUXNQ NHPWUmhKSzVyPUCuNFU5KM7:TR?= MWKyOVg4QDN|MR?=
SU-DHL2 NEjvS|BEgXSxdH;4bYMhSXO|YYm= NYX2[o1NPzJiaB?= NYPpWXlYTE2VTx?= Mkn1TWM2OD1yLkCxJO69VQ>? MUiyOVg4QDN|MR?=
OCI-LY7 M3\iPWN6fG:2b4jpZ{BCe3OjeR?= NHLJTJA4OiCq NXvKO3U2TE2VTx?= MVHJR|UxRTBwMEixJO69VQ>? MkHqNlU5Pzh|M{G=
SU-DHL6 MnXZR5l1d3SxeHnjJGF{e2G7 MV23NkBp M37pW2ROW09? NEnqVGRKSzVyPUCuOFgzKM7:TR?= NEfRWZQzPTh5OEOzNS=>
Jeko-1 NXzSdppyS3m2b4TvfIlkKEG|c3H5 Mlu5O|IhcA>? M125fGROW09? M1m4[WlEPTB;MD6wNlkh|ryP NH6wdIYzPTh5OEOzNS=>
JVM-2 NFf0UHVEgXSxdH;4bYMhSXO|YYm= M3HvOVczKGh? NFLrbZVFVVOR M1TlVWlEPTB;MD6wNUDPxE1? MXOyOVg4QDN|MR?=
Rec-1 M2\SR2N6fG:2b4jpZ{BCe3OjeR?= MWW3NkBp MYDEUXNQ MVrJR|UxRTBwMEi3JO69VQ>? NYTDbZp4OjV6N{izN|E>
Z-138 NIS1U4NEgXSxdH;4bYMhSXO|YYm= NGrQUo44OiCq MmX0SG1UVw>? NH;5WVJKSzVyPUCuNFE{KM7:TR?= MUOyOVg4QDN|MR?=
H9 MV\DfZRwfG:6aXOgRZN{[Xl? NGGze5E4OiCq NHXw[ZFFVVOR NXzwXY9WUUN3ME2wMlYh|ryP NWPRSWJ2OjV6N{izN|E>
HH M2DqcmN6fG:2b4jpZ{BCe3OjeR?= NGHOWnI4OiCq M3\rcmROW09? MlW4TWM2OD1yLkeg{txO Ml\4NlU5Pzh|M{G=
DND41 NXr3UnJGS3m2b4TvfIlkKEG|c3H5 NID3WGQ4OiCq NILx[odFVVOR NYrxO2pmUUN3ME2wMlEh|ryP NF\5T2UzPTh5OEOzNS=>
CCL119 NV3ZR2VsS3m2b4TvfIlkKEG|c3H5 NGfQUIY4OiCq Mlj2SG1UVw>? MkHSTWM2OD1yLkC2NkDPxE1? MmjKNlU5Pzh|M{G=
J.Cam 1.6 MkftR5l1d3SxeHnjJGF{e2G7 NFj0SWY4OiCq M2KwUmROW09? M2rY[GlEPTB;MD6xNFUh|ryP NVewWoV2OjV6N{izN|E>
Sup-T1 MWLDfZRwfG:6aXOgRZN{[Xl? M13XdFczKGh? NGPFO|VFVVOR MWnJR|UxRTJwMUSyJO69VQ>? M2GwclI2QDd6M{Ox
Tib 152 NWnxc5MxS3m2b4TvfIlkKEG|c3H5 MUK3NkBp MUHEUXNQ M1PYc2lEPTB;MD64JO69VQ>? M{HEWVI2QDd6M{Ox
MCF7 Mn\KSpVv[3Srb36gRZN{[Xl? NH\h[mk2KM7:TR?= MknLNlQhcA>? M3LFNmROW09? NVHFfmM6UW6mdXPld{BIOi:PIHHydoV{fA>? MkLJNlU5OzR2MEG=
MDA-MB-231 MX\GeY5kfGmxbjDBd5NigQ>? NGLKW|c2KM7:TR?= NVnXfFRrOjRiaB?= NXvaNYlWTE2VTx?= NGHxVXFKdmS3Y3XzJGc{N01iYYLy[ZN1 MYKyOVg{PDRyMR?=
MCF7 NFvWOVdHfW6ldHnvckBCe3OjeR?= Mn[xOUDPxE1? MlXlNlQhcA>? MmPzSG1UVw>? M3TJbmRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= MVWyOVg{PDRyMR?=
MCF7 MYTGeY5kfGmxbjDBd5NigQ>? MWO1JO69VQ>? NHf3VJEzPCCq NYTJSVdwTE2VTx?= MoqxSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> MVmyOVg{PDRyMR?=
MCF7 MVzGeY5kfGmxbjDBd5NigQ>? MnTZOUDPxE1? M3XGbFI1KGh? M4e1NGROW09? M4DHTmRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG= MknVNlU5OzR2MEG=
MCF7 NUnOe3Q4TnWwY4Tpc44hSXO|YYm= MmPpOUDPxE1? MU[yOEBp MUXEUXNQ MYfJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> MkPFNlU5OzR2MEG=
MCF7 MVjGeY5kfGmxbjDBd5NigQ>? M2HxNVUh|ryP NHS1S3UzPCCq MXzEUXNQ MnqxTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyO{BMcXBz NHnKRnUzPTh|NESwNS=>
MDA-MB-231 MULGeY5kfGmxbjDBd5NigQ>? NEDsdIE2KM7:TR?= MnjPNlQhcA>? Mkn2SG1UVw>? MX3E[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ NXLOOFQ5OjV6M{S0NFE>
MDA-MB-231 M1f1PGZ2dmO2aX;uJGF{e2G7 NX:2e4FjOSEQvF2= NH7weYEzPCCq MYXEUXNQ MWDJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> M1PsNVI2QDN2NECx
MDA-MB-231 NYP6[HVNTnWwY4Tpc44hSXO|YYm= MXm1JO69VQ>? M4rIPFI1KGh? MmrDSG1UVw>? NH\uOopF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx MXuyOVg{PDRyMR?=
MDA-MB-231 MmDxSpVv[3Srb36gRZN{[Xl? MWO1JO69VQ>? Mo\HNlQhcA>? MX\EUXNQ M{jP[mlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy M1LUXFI2QDN2NECx
MDA-MB-231 NEXl[nRHfW6ldHnvckBCe3OjeR?= NWPIeoVuPSEQvF2= NXXTUVdbOjRiaB?= MWDEUXNQ NES5XmNKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= NUThXXNWOjV6M{S0NFE>
MDA-MB-231 NEPaZpVHfW6ldHnvckBCe3OjeR?= NYTRdVV5PSEQvF2= MkLaNlQhcA>? MXzEUXNQ MWPJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEWz MVGyOVg{PDRyMR?=
MCF7 Mn3jRZBweHSxc3nzJGF{e2G7 MoHlOUDPxE1? NIrrOJAzPCCq MmL4SG1UVw>? NUfMdJA4UW6mdXPld{BieG:ydH;0bYMh\GWjdHi= M3XxcFI2QDN2NECx
MDA-MB-231 MXnBdI9xfG:|aYOgRZN{[Xl? M{\UOlUh|ryP MmC3NlQhcA>? MnjrSG1UVw>? MUXJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? M{[zVVI2QDN2NECx
MCF7 NUfsdZZwTnWwY4Tpc44hSXO|YYm= MVexJO69VQ>? NUHPZXk6PzJiaB?= MU\EUXNQ MWfJcoR2[2W|IHH1eI9xcGGpaXOg[IVifGh? MlTsNlU5OzR2MEG=
MDA-MB-231 NHr1bm5HfW6ldHnvckBCe3OjeR?= MXuxJO69VQ>? M2TLdFczKGh? MkO3SG1UVw>? MV7JcoR2[2W|IHH1eI9xcGGpaXOg[IVifGh? MXuyOVg{PDRyMR?=
U-2 OS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn0OVAh|ryP MX6yOEBp NUC2T|hGTE2VTx?= NGPjZ|RKSzVyPUG2MlYh|ryP M1zCVlI2Pzl{OEGx
MG-63 M{XiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLVOVAh|ryP NYfUR25VOjRiaB?= M1TnOmROW09? M1vDU2lEPTB;OT61JO69VQ>? MUWyOVc6OjhzMR?=
U-2 OS MV;BdI9xfG:|aYOgRZN{[Xl? MUm1JO69VQ>? MnvsNlQhcA>? NX;LOIRLTE2VTx?= NF\HUGJKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NX;q[o5pOjV5OUK4NVE>
MG-63 MU\BdI9xfG:|aYOgRZN{[Xl? MYG1JO69VQ>? NGO5dWEzPCCq NU\uRWxiTE2VTx?= NYXNVphqUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? NFznZY8zPTd7MkixNS=>
U-2 OS MYDGeY5kfGmxbjDBd5NigQ>? NIPxWFA2KM7:TR?= MXKyOEBp MkL0SG1UVw>? NVO0XIQxWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq Ml\1NlU4QTJ6MUG=
MG-63 MX7GeY5kfGmxbjDBd5NigQ>? Ml7rOUDPxE1? NV3vXlBLOjRiaB?= NVvOTZFJTE2VTx?= MVLQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> NXyw[phPOjV5OUK4NVE>
PANC-1 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy1NEDPxE1? M3:0TFI1KGh? MXTEUXNQ MVrJR|UxRTdwMTFOwG0> MkH2NlU3OzJ{MkW=
BxPC-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rLT|UxKM7:TR?= MoqzNlQhcA>? NUHEWVFRTE2VTx?= MnXCTWM2OD14Lkig{txO NWDOO2wzOjV4M{KyNlU>
PANC-1 NVr2UG9OTnWwY4Tpc44hSXO|YYm= NV7qUIl6PSEQvF2= NXrNXXRWOjRiaB?= M4PZWWROW09? M1zmdmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? NI\UT2UzPTZ|MkKyOS=>
BxPC-3 MljHSpVv[3Srb36gRZN{[Xl? Ml\XOUDPxE1? M3vuT|I1KGh? NVzBUJYzTE2VTx?= MoXCTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckBIOi:PIIDoZZNm Mkm5NlU3OzJ{MkW=
PANC-1 NVG2TpJOTnWwY4Tpc44hSXO|YYm= M1fDXlUh|ryP MUOyOEBp NVT2TI0yTE2VTx?= M4nmRWlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp MU[yOVY{OjJ{NR?=
BxPC-3 MUjGeY5kfGmxbjDBd5NigQ>? NVuwN282PSEQvF2= MmLVNlQhcA>? M1rp[mROW09? M324fmlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp M{j0NlI2PjN{MkK1
SKOV3 M1vsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7MN21{OTByIN88US=> M3TaW|I1KGh? NYXyOlF2TE2VTx?= MnHkTWM2OD1{MD60PEDPxE1? MYKyOVYzPDd3MB?=
OVCAR4 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;z[|ExOCEQvF2= NVPRUVRVOjRiaB?= NWnWdZZ1TE2VTx?= MoD4TWM2OD1{Mj6xN{DPxE1? M2HOfFI2PjJ2N{Ww
SKOV3 M1nmN2Z2dmO2aX;uJGF{e2G7 M{TSPFUh|ryP NX36SVdkPzJiaB?= MnGySG1UVw>? NIr6OplKdmS3Y3XzJGczN01iYYLy[ZN1 NHW5N5YzPTZ{NEe1NC=>
OVCAR4 NEfaPVZHfW6ldHnvckBCe3OjeR?= M1r6RVUh|ryP MWq3NkBp NHPweIxFVVOR MlPOTY5lfWOnczDHNk9OKGG{cnXzeC=> NYe2fIVkOjV4MkS3OVA>
SKOV3 MVXBdI9xfG:|aYOgRZN{[Xl? NUHUVI1jPSEQvF2= MUmyOEBp M{Ts[GROW09? NU\6S3hJUW6mdXPld{BieG:ydH;zbZM> M3nDWFI2PjJ2N{Ww
OVCAR4 NYLnOIVkSXCxcITvd4l{KEG|c3H5 MXG1JO69VQ>? MVqyOEBp NYjIdnViTE2VTx?= MoC1TY5lfWOnczDhdI9xfG:|aYO= NVX2cppCOjV4MkS3OVA>
AGS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO2b4MzPSEQvF2= NWjKS5NoOjRiaB?= NWrnc2V{TE2VTx?= NEGyXIpKSzVyPUG5MlA6KM7:TR?= MXeyOVYxQTl{Mx?=
NCI-N78 NUHrVWxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjsXpE{OjVizszN NUTSU3V6OjRiaB?= MX7EUXNQ MoHxTWM2OD1{Nj6zN{DPxE1? NWf6Wop[OjV4MEm5NlM>
AGS MX;BdI9xfG:|aYOgRZN{[Xl? MnLDOUDPxE1? MnPhNlQhcA>? MUTEUXNQ NYm2[pJVUW6mdXPld{BieG:ydH;zbZM> NVPxU5Z{OjV4MEm5NlM>
NCI-N78 NIjqboxCeG:ydH;zbZMhSXO|YYm= M2r1TlUh|ryP MmC4NlQhcA>? MXzEUXNQ NU\OPJk6UW6mdXPld{BieG:ydH;zbZM> MlvmNlU3ODl7MkO=
AGS MmXySpVv[3Srb36gRZN{[Xl? NX3aNlZxPSEQvF2= NX7Hb3R[OjRiaB?= NYnkenFKTE2VTx?= M3;wXWlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NIrBeFIzPTZyOUmyNy=>
NCI-N78 M4LTbmZ2dmO2aX;uJGF{e2G7 NGDFbYk2KM7:TR?= MU[yOEBp NXvIdod4TE2VTx?= M3;SR2lv\HWlZYOgeIhmKGG3dH;wbIFogQ>? MmHkNlU3ODl7MkO=
HSC-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nKNVEh|ryP M{XJOlQ5KGh? MXPJR|UxRTBwNUSg{txO NX;nOW03OjV|Nk[xOFM>
GB30 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnkU5FbOSEQvF2= Mkj2O{Bl NY\HUnBZTE2VTx?= NF\qWmZKSzVyPUCuNFEyKM7:TR?= MWeyOVExPjR{OB?=
GB9 M3TUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\0NUDPxE1? Mmn5O{Bl M{XIVmROW09? M4jPU2lEPTB;MD6wNlQh|ryP NH\5UGQzPTFyNkSyPC=>
GB169 M1;pUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPxSW8yKM7:TR?= M1vHNVch\A>? NV\vcW57TE2VTx?= NHXsPFlKSzVyPUCuNFMzKM7:TR?= MmjqNlUyODZ2Mki=
T24 M3vVSWZ2dmO2aX;uJGF{e2G7 MlLnNUDPxE1? MlixOFghcA>? Mo\HSG1UVw>? M3\rcGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= M3PBSVI{PDB|NkOz
RT4 MYHGeY5kfGmxbjDBd5NigQ>? NGqxdZoyKM7:TR?= MUO0PEBp MUPEUXNQ M2S0U2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= M2ryTVI{PDB|NkOz
UM-UC-3 NF;1RVlHfW6ldHnvckBCe3OjeR?= MVqxJO69VQ>? M2rIc|Q5KGh? M{LlemROW09? NHnPbmpKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MViyN|QxOzZ|Mx?=
T24 Mnv6RZBweHSxc3nzJGF{e2G7 Mk\GN{4yPiEQvF2= MV25OkBp MYLEUXNQ M4PyVWlEPTB;MD6wN|A3KM7:TR?= NVTNeXY1OjN2MEO2N|M>
RT4 MoPXRZBweHSxc3nzJGF{e2G7 M1XrUFMvOTZizszN MXe5OkBp NV\1SnFVTE2VTx?= MkXqTWM2OD1yLkGxPVgh|ryP NXH5O2c3OjN2MEO2N|M>
UM-UC-3 MYLBdI9xfG:|aYOgRZN{[Xl? MoXMN{4yPiEQvF2= NIHlcJY6PiCq MWfEUXNQ MVrJR|UxRTBwMES0PUDPxE1? M1TucVI{PDB|NkOz
OVCAR-5 M3PRPWZ2dmO2aX;uJGF{e2G7 MlX4OVAhdk1? NIXxTVJKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= MnnGNlM{OzR|Mke=
SKOV3ip2 NWD1dZF2TnWwY4Tpc44hSXO|YYm= NH7sfFE2OCCwTR?= NHvxVZRKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= MUKyN|M{PDN{Nx?=
S462 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxNFAh|ryP NGntc284OiCq MWDEUXNQ MXXBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp MoPBNlM{OjhzMUS=
2884 M1ftRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W0V|ExOCEQvF2= NGPtS284OiCq MYDEUXNQ M123ZWF1fGWwdXH0[ZMh[2WubDDndo94fGh? M{HyXVI{OzJ6MUG0
2885 M4TNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzvclZDOTByIN88US=> MUG3NkBp NETUOFhFVVOR M4TXVmF1fGWwdXH0[ZMh[2WubDDndo94fGh? NGi4emIzOzN{OEGxOC=>
CRL-2396 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHsd2gyODBizszN MUD3ZZRmeg>? M3nEeGlEPTB;MD6wPVIh|ryP NVfIbYZKOjNzNUO1NlQ>
TIB-48 NHjObJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M122bFExOCEQvF2= NGXwXXF4[XSnch?= MoPjTWM2OD1yLkC4PEDPxE1? M4r6[VI{OTV|NUK0
CRL-2396 M1nwbWN6fG:2b4jpZ{BCe3OjeR?= MXqxJO69VQ>? M{TrNVQ5KGh? MXT3ZZRmeg>? MXzJcoR2[2W|IHHwc5B1d3Orcx?= NGrabWEzOzF3M{WyOC=>
TIB-48 MWjDfZRwfG:6aXOgRZN{[Xl? MVmxJO69VQ>? M{jQW|Q5KGh? NHv5cm94[XSnch?= MnrBTY5lfWOnczDhdI9xfG:|aYO= NH3hN2YzOzF3M{WyOC=>
AGS NV7id5BCS3m2b4TvfIlkKEG|c3H5 M{jXSVAvPSEQvF2= NUL0VnI2OjRiaB?= MWTEUXNQ M2jRSmRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu Ml:xNlI6PzJ4MUG=
FLO-1 NFvuVnBEgXSxdH;4bYMhSXO|YYm= NGnVVWMxNjVizszN NYLsd25zOjRiaB?= NX21O3h2TE2VTx?= MkTySIVkemWjc3XzJINmdGxic4Xyeol3[Wx? NH3ESo8zOjl5Mk[xNS=>
OE33 NGWwVWJEgXSxdH;4bYMhSXO|YYm= NVn1UGdzOC53IN88US=> MnrRNlQhcA>? NIK4d2lFVVOR MnHhSIVkemWjc3XzJINmdGxic4Xyeol3[Wx? Mn\xNlI6PzJ4MUG=
SKLMS MoW2R5l1d3SxeHnjJGF{e2G7 NGLsO5k4PSCwTR?= NUDlTHRRQTZiaB?= NHXXOWRKdmS3Y3XzJIFxd3C2b4Ppdy=> M4mzV|IzQDJzOUm3
Leio285 NUj3eJp1S3m2b4TvfIlkKEG|c3H5 NILCOpI4PSCwTR?= NVPwPIhSQTZiaB?= NHHyNVlKdmS3Y3XzJIFxd3C2b4Ppdy=> M3r1XlIzQDJzOUm3
Mes-Sa M3;l[WN6fG:2b4jpZ{BCe3OjeR?= MnnkO|Uhdk1? M{jWVlk3KGh? M1TZTmlv\HWlZYOgZZBweHSxc3nz NEfJ[FEzOjh{MUm5Oy=>
DAOY MYTDfZRwfG:6aXOgRZN{[Xl? NYjIdlJxOTBizszN MnLkO|IhcA>? NUTDSoV3TE2VTx?= MVrJR|UxRTBwMESg{txO MmC5NlI3Pjl|M{W=
IMR32 MULDfZRwfG:6aXOgRZN{[Xl? M1PifFExKM7:TR?= NGTz[4E4OiCq NXr4e5FETE2VTx?= M13mTWlEPTB;MD6wN{DPxE1? M2n0bVIzPjZ7M{O1
Molt-4 M{LGeGN6fG:2b4jpZ{BCe3OjeR?= NYTvdFZNOTBizszN NHTqZWg4OiCq M3TrPGROW09? NI\NfHNKSzVyPUCuNFIh|ryP NFGwcYwzOjZ4OUOzOS=>
MOLM-13 NFzyOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3KxeVMh|ryP MXG3NkBp Mm\ISIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MX[yNlQ5QDJ2OR?=
HL-60 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrhN{DPxE1? M3;EbFczKGh? NGHOdnZFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MormNlI1QDh{NEm=
MV4-11 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrxUZI5OyEQvF2= M3nSV|czKGh? M4rO[mRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NE\Re5kzOjR6OEK0PS=>
SKM-1 NYHsWGZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK4Ro5FOyEQvF2= MYC3NkBp NV3jUVBGTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NVzie3lqOjJ2OEiyOFk>
SH2 M2\ZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnxN{DPxE1? M3jkdlczKGh? M4TZSWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= M4rFSFIzPDh6MkS5
NOMO-1 M37vO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOzJO69VQ>? NILSXWQ4OiCq NVTyZYRQTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MVWyNlQ5QDJ2OR?=
OCL-AML2 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO1N{DPxE1? Mn;qO|IhcA>? MVHEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MUGyNlQ5QDJ2OR?=
PL-21 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XES|Mh|ryP NWHWSJlqPzJiaB?= MX;EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MVOyNlQ5QDJ2OR?=
KG-1 NU[zfpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[4VVNxOyEQvF2= M3TjWVczKGh? M4LXeWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= M{ThV|IzPDh6MkS5
A172 NF7q[ZVEgXSxdH;4bYMhSXO|YYm= Ml3DNVAxKM7:TR?= MmPzNlQhcA>? MnXESG1UVw>? MnXxTWM2OD1yLkGyNEDPxE1? NVTvenlnOjJ{N{SzPVk>
U87 NIjSc5REgXSxdH;4bYMhSXO|YYm= MV[xNFAh|ryP MXSyOEBp Mmq4SG1UVw>? NGfpVppKSzVyPUCuNVA2KM7:TR?= NYDwOFU1OjJ{N{SzPVk>
U251 MVnDfZRwfG:6aXOgRZN{[Xl? NVf6co42OTByIN88US=> NWH0SYZ1OjRiaB?= NETrOZVFVVOR NY\nNFF1UUN3ME2wMlExOCEQvF2= Mm\aNlIzPzR|OUm=
T98 NYnBcXV1S3m2b4TvfIlkKEG|c3H5 NVfHTllyOTByIN88US=> M3[zd|I1KGh? NVHwTVhiTE2VTx?= NVzJe29DUUN3ME2wMlEzPSEQvF2= NHTtPFQzOjJ5NEO5PS=>
LN18 M1qxfWN6fG:2b4jpZ{BCe3OjeR?= M1zNR|ExOCEQvF2= MUiyOEBp NHzMTnBFVVOR MmS5TWM2OD1yLkKxNEDPxE1? NF\0UnkzOjJ5NEO5PS=>
LN443 NIjieZREgXSxdH;4bYMhSXO|YYm= MljGNVAxKM7:TR?= NYLkSlZMOjRiaB?= Mo\CSG1UVw>? NEDrWIVKSzVyPUCuNlIxKM7:TR?= NHrCd3YzOjJ5NEO5PS=>
HF66 NIfQSFNEgXSxdH;4bYMhSXO|YYm= MkDHNVAxKM7:TR?= MYeyOEBp Ml:zSG1UVw>? MmXUTWM2OD1yLkKyOUDPxE1? NEHFOlYzOjJ5NEO5PS=>
HF2303 Mk\UR5l1d3SxeHnjJGF{e2G7 NHfzTYkyODBizszN NWTxdIJrOjRiaB?= NVTsSnVxTE2VTx?= MYPJR|UxRTBwME[wJO69VQ>? M1nW[lIzOjd2M{m5
HF2359 NVnoUXBoS3m2b4TvfIlkKEG|c3H5 NEDCRWMyODBizszN NULKeFR5OjRiaB?= M2rMbGROW09? M4W1VWlEPTB;MD6wOlAh|ryP NXPDRXhKOjJ{N{SzPVk>
HF2414 NInrUZhEgXSxdH;4bYMhSXO|YYm= NWLmXGhsOTByIN88US=> MknKNlQhcA>? M4DETGROW09? MlHuTWM2OD1yLkC4NEDPxE1? MWCyNlI4PDN7OR?=
A-673 NU\KcFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrUZm8yOCEQvF2= Ml\JPVYhcA>? NET2O2pFVVOR NIXDOnVKSzVyPUCuNFMzKM7:TR?= MlfqNlE1PDh3OUG=
TC-32 M1HUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jtb|ExKM7:TR?= M1jmbVk3KGh? M3vHSGROW09? NVjpXIREUUN3ME2wMlA{QSEQvF2= NHmwZWgzOTR2OEW5NS=>
TC-71 M{SxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zIelExKM7:TR?= MWe5OkBp NFvnOY5FVVOR M{fVZmlEPTB;MD6xNFIh|ryP NEHhVIYzOTR2OEW5NS=>
SK-N-MC NEXoeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHJR4gyOCEQvF2= MUG5OkBp NWPzV5NwTE2VTx?= M1nhSGlEPTB;MD6wO|Ih|ryP MofLNlE1PDh3OUG=
CHLA-9 M1:yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfxNVAh|ryP NUP0c3pMQTZiaB?= M1XaNWROW09? NVP3NVE3UUN3ME2wMlAyQCEQvF2= NXj6NFJXOjF2NEi1PVE>
CHLA-10 M2TXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnrd21kOTBizszN MVW5OkBp MUPEUXNQ MljyTWM2OD1yLkC2NEDPxE1? NFXzWFczOTR2OEW5NS=>
CHLA-25 M3v0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvGNVAh|ryP MXi5OkBp Mo\YSG1UVw>? M3PwPWlEPTB;MD6xOlgh|ryP NF\4NGEzOTR2OEW5NS=>
CHLA-32 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjWNVAh|ryP MknKPVYhcA>? MXHEUXNQ M1TXR2lEPTB;MD6xN|Yh|ryP NXXNTnB6OjF2NEi1PVE>
CHLA-56 NU[5VJlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3JeIkyOCEQvF2= Mk\iPVYhcA>? MnPoSG1UVw>? NUPQeWJTUUN3ME2xNEDPxE1? MUmyNVQ1QDV7MR?=
CHLA-258 NULjN2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[xNEDPxE1? MX65OkBp MUjEUXNQ MW\JR|UxRTBwMUOyJO69VQ>? MWWyNVQ1QDV7MR?=
COG-E-352 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTXNVAh|ryP NX\2Z25mQTZiaB?= MX3EUXNQ NH3GTXVKSzVyPUCuNFQ{KM7:TR?= MoXMNlE1PDh3OUG=
CHLA-90 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDVfWQyOCEQvF2= M331[Fk3KGh? M2nSXWROW09? MkXFTWM2OD1yLkC2NUDPxE1? MlXINlE1PDh3OUG=
CHLA-119 NWmwTXJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LCWlExKM7:TR?= MXG5OkBp NFnFV41FVVOR MUHJR|UxRTBwMEKyJO69VQ>? MkLBNlE1PDh3OUG=
CHLA-122 NVTZUIo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOxNEDPxE1? MX:5OkBp NV:yboZ6TE2VTx?= NUXnb4FbUUN3ME2wMlAyQSEQvF2= M{LnbVIyPDR6NUmx
CHLA-136 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf4NHAyOCEQvF2= MYS5OkBp M2LsSmROW09? M4n3[mlEPTB;MD6wN|kh|ryP Ml;RNlE1PDh3OUG=
CHLA-140 NYnIT4N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7rV25LOTBizszN NUDERpA2QTZiaB?= MVLEUXNQ M2XlXWlEPTB;MD6wNlYh|ryP M2fxRlIyPDR6NUmx
LA-N-6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDkNVAh|ryP NVTIfnBxQTZiaB?= MYLEUXNQ M4HMOmlEPTB;MD6wOVQh|ryP NWfIOIJqOjF2NEi1PVE>
NB-1643 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxNEDPxE1? MWG5OkBp NFfSRmhFVVOR NH;Xc2RKSzVyPUCuNFM4KM7:TR?= MV[yNVQ1QDV7MR?=
NB-EBc1 NXza[HNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXCT2gyOCEQvF2= Mn3ZPVYhcA>? NYP0NXZUTE2VTx?= Mlv1TWM2OD1yLkC1NEDPxE1? NV33Zo1WOjF2NEi1PVE>
SK-N-BE-1 NEDIcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNEDPxE1? MWO5OkBp NIfJ[FdFVVOR MlW0TWM2OD1yLkCyPEDPxE1? NGr6Sm0zOTR2OEW5NS=>
SK-N-BE-2 NGTCW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvF[pUyOCEQvF2= MVK5OkBp MXjEUXNQ MmK4TWM2OD1yLkCzOkDPxE1? M{\DZ|IyPDR6NUmx
SMS-KAN MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:3U|ExKM7:TR?= M{TXUlk3KGh? NEmxW5dFVVOR MlTOTWM2OD1yLkCzOEDPxE1? NUL3S29NOjF2NEi1PVE>
SMS-KANR MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLYUZNUOTBizszN Ml;MPVYhcA>? NEfFfXZFVVOR M{f1fGlEPTB;MD6wNlYh|ryP NHPUeoUzOTR2OEW5NS=>
SMS-KCN NGfSXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOxNEDPxE1? NULlTlF3QTZiaB?= NVr3Z|NVTE2VTx?= MXTJR|UxRTBwMEG5JO69VQ>? MWqyNVQ1QDV7MR?=
SMS-KCNR M3y0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexNEDPxE1? NWnWVoVSQTZiaB?= NG\6UnBFVVOR M17G[mlEPTB;MD6wNVAh|ryP M1XIdFIyPDR6NUmx
SMS-LHN M3n2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\aT|ExKM7:TR?= M{Pad|k3KGh? MYLEUXNQ MXjJR|UxRTBwMEOyJO69VQ>? Ml7UNlE1PDh3OUG=
SMS-MSN NUntOXBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxNEDPxE1? NHfibmk6PiCq MmmwSG1UVw>? NHf6OotKSzVyPUCuNFIzKM7:TR?= Mn[0NlE1PDh3OUG=
SMS-SAN MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj1eYM{OTBizszN NX\WVmI{QTZiaB?= M1\rU2ROW09? MkXMTWM2OD1yLkCyNEDPxE1? NFSyO|gzOTR2OEW5NS=>
Granta-4 MlXYR5l1d3SxeHnjJGF{e2G7 MoLsNVAh|ryP NE\RZY04KGR? NV7ZTGQzUUN3ME2wMlA1OCEQvF2= NXqzOXdkOjF{OUG4Olc>
DB NVTyV3JrS3m2b4TvfIlkKEG|c3H5 NEP6XYYyOCEQvF2= M4f3NVch\A>? NHW0fHlKSzVyPUCuNFQzKM7:TR?= MWGyNVI6OTh4Nx?=
RL Ml[wR5l1d3SxeHnjJGF{e2G7 MX2xNEDPxE1? NESxOIs4KGR? NWjjVos2UUN3ME2wMlAyPSEQvF2= NYP3PJppOjF{OUG4Olc>
K562 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXyNVAh|ryP MXK5OkBp MUHJR|UxRTBwMEi3JO69VQ>? M{nscFIyODlzNkOz
LAMA-84 NYLHcIlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuxNEDPxE1? MXO5OkBp MnHlTWM2OD1yLkC1O{DPxE1? M4\l[|IyODlzNkOz
MM15 NHLrZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PaUFQh|ryP NVL4OFFwPzJiaB?= MmjsSG1UVw>? M2DBVmlEPTB;MD6xN{DPxE1? MVeyNFM5Ojh2NB?=
OPM1 NGrGTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\LcFZxPCEQvF2= MV63NkBp NVjucmxETE2VTx?= NX3yS5k5UUN3ME2wMlA{KM7:TR?= MlrYNlA{QDJ6NES=
RPM1 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPDU3V2PCEQvF2= Ml\hO|IhcA>? M1;jRWROW09? NWLzXVdEUUN3ME2xNE4{OiEQvF2= NH3rc|QzODN6Mki0OC=>
INA6 M4C3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnJT3hsPCEQvF2= MV[3NkBp NYTFSZpLTE2VTx?= NVrLV4ZuUUN3ME2wMlAxOiEQvF2= M{fZZlIxOzh{OES0
OPM2 NFe1TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjpcFg6PCEQvF2= Mmf4O|IhcA>? Ml\SSG1UVw>? Mk\5TWM2OD12LkO3JO69VQ>? MnzmNlA{QDJ6NES=
MM1R MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYS0JO69VQ>? NX7E[5BMPzJiaB?= NIPkco5FVVOR MoD2TWM2OD1zLk[4JO69VQ>? MW[yNFM5Ojh2NB?=
DOX40 M4nRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrWbGt2PCEQvF2= NUn3dpNKPzJiaB?= M1n1XmROW09? MVTJR|UxRTVwNEig{txO MnXjNlA{QDJ6NES=
LR5 NYrRR4t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTROEDPxE1? NH7Fe5E4OiCq MnixSG1UVw>? NEHWNWhKSzVyPUKuOVMh|ryP MUSyNFM5Ojh2NB?=
U266 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjES2dZPCEQvF2= MYK3NkBp NXvyXpVtTE2VTx?= NGL0VWlKSzVyPUGuOFMh|ryP MnTYNlA{QDJ6NES=
RD M1TqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuxZ|QyOCEQvF2= MUW5OkBp M3rtZ2lEPTB;MD6yNlgh|ryP M4TE[lIxOTB6M{O4
Rh41 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xNEDPxE1? M4DXeFk3KGh? NXXOeGdHUUN3ME2wMlA6OCEQvF2= M4LuW|IxOTB6M{O4
Rh30 NHi3NoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGxNEDPxE1? NITtS3E6PiCq NV:0UlZxUUN3ME2wMlI{OCEQvF2= M1fqclIxOTB6M{O4
BT-12 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XRU|ExKM7:TR?= MX[5OkBp NF7ZXnpKSzVyPUCuNFYxKM7:TR?= NI[xd5kzODFyOEOzPC=>
CHLA-266 M1uwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOxNEDPxE1? MXW5OkBp MUfJR|UxRTBwMEeyJO69VQ>? NXTCdVE4OjBzMEizN|g>
TC-71 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\aeWd4OTBizszN NEDIbJY6PiCq MmrYTWM2OD1yLkGwNkDPxE1? NFK1bGozODFyOEOzPC=>
SJ-GBM2 M{LGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnqZnBuOTBizszN MXi5OkBp MVnJR|UxRTBwMEWwJO69VQ>? MV6yNFExQDN|OB?=
NALM-6 M4PIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrNT44yOCEQvF2= NGraSI06PiCq NHHoNVRKSzVyPUCuNFYzKM7:TR?= MmnxNlAyODh|M{i=
COG-LL-317 M1PqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\tNVAh|ryP Mn7uPVYhcA>? MkXMTWM2OD1yLkC0O{DPxE1? NWXITIxwOjBzMEizN|g>
RS4-11 Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn2SVNIOTBizszN MUi5OkBp NGWyeVBKSzVyPUCuNFE5KM7:TR?= NV;tPJpxOjBzMEizN|g>
MOLT-4 NFTscYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXS[3I5OTBizszN MVu5OkBp MlzFTWM2OD1yLkCyOkDPxE1? NYHXdnN2OjBzMEizN|g>
CCRF-CEM Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxNEDPxE1? NUmx[mRKQTZiaB?= M365XmlEPTB;MD6wPVQh|ryP NVLhVnV1OjBzMEizN|g>
Kasumi-1 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjFbZBKOTBizszN NFy1XGg6PiCq MoPHTWM2OD1yLkGwN{DPxE1? MWqyNFExQDN|OB?=
Karpas-299 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uxflExKM7:TR?= NVnXOVRRQTZiaB?= M3rWb2lEPTB;MD6wN|gh|ryP MUeyNFExQDN|OB?=
Ramos-RA1 M1:zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHqNVAh|ryP NWTlZo9wQTZiaB?= NGDheGRKSzVyPUCuNVI4KM7:TR?= Ml64NlAyODh|M{i=

... Click to View More Cell Line Experimental Data

体内研究 MLN8237口服处理,显著降低肿瘤负担,按15 mg/kg 和30 mg/kg剂量处理肿瘤生长抑制率(TGI) 分别为42%和80%,且与对照组相比,延迟小鼠寿命。[2] MLN8237 (30 mg/kg) 与Cisplatin (2 mg/kg) 联用作用于FLO-1移植瘤,与单独用药相比,抗癌活性增强,伴随着Ki-67表达受抑制,细胞核p73蛋白和cleaved caspase 3表达增强。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

Aurora A放射性闪光板酶实验:

进行Aurora A放射性闪光板酶实验,测定体外MLN8237抑制程度。在Sf9细胞中表达重组Aurora A,然后使用GST亲和层析进行纯化。Aurora A 肽底物与生物素联合形成生物素-GLRRASLG。在50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween-20, 2 μM 肽底物, 3.3 μCi/mL [γ-33 P]ATP 2 μM, 和浓度不断增高的MLN8237 的混合物中进行Aurora A激酶 (5 nM)实验。
细胞实验:[2]
+ 展开
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, 和U266
  • Concentrations: 溶于DMSO,终浓度为~10 μM
  • Incubation Time: 24, 48, 和72小时
  • Method: 使用不同浓度MLN8237处理细胞24, 48,和72小时。通过MTT实验测定细胞活力,通过测定 3[3H]-胸甘渗透而测定细胞增殖。为了分析细胞周期,使用70%乙醇在-20oC下使细胞通透,然后与50 μg/mL PI 和20 单位/mL RNase-A温育。 通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件分析DNA含量。 为了测定凋亡和衰老,使用异硫氰酸荧光素-annexin V和PI对细胞进行染色。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件测定凋亡细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下接种 MM1.S 细胞的SCID鼠
  • Formulation: 在10% 2-羟丙基-β-环糊精/1%碳酸氢钠中配制
  • Dosages: ~30 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
15% Captisol
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 518.92
化学式

C27H20ClFN4O4

CAS号 1028486-01-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品

Tags: 购买Alisertib (MLN8237) | Alisertib (MLN8237)供应商 | 采购Alisertib (MLN8237) | Alisertib (MLN8237)价格 | Alisertib (MLN8237)生产 | 订购Alisertib (MLN8237) | Alisertib (MLN8237)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID